Pogue Mahone
Swiftie Fan Club President
- Joined
- Feb 22, 2006
- Messages
- 135,011
- Caf Award
- Caf Lifetime Achievement Award 2021
I thought that normally drug companies don't release commercially in a particular region until their own and another regulatory body approve it e.g. in Europe EMEA and another one, for the US FDA plus another one - could be wrong but I thought I'd read that somewhere.
Maybe I dreamed it.
I also thought that therapeutic drugs usually required 2 separate stage 3 trials but vaccines didn't. Again could be making it up as I go along.
You must have dreamed it!
Drug companies will always launch in whatever region they get approval, whether or not it has been approved somewhere else. It’s actually quite common to have differing timelines with a drug widely available in one region but not yet licensed in another.
Something else which complicates this is “the fourth hurdle”, which is cost effectiveness. Governments won’t typically make a drug available immediately after it’s licensed. They will refer it to their health economics body (NICE in the UK) to see if it provides value for money. Which might involve a lot of back and forth with the company regarding price and quality of data. Sometimes they even request new clinical trials. This can delay patient access for a year or longer after license. I suspect the manufacturer of a successful vaccine might find this particular hurdle a lot easier to get over than usual!